Epigenetic-based therapies for Friedreich ataxia

Frontiers in Genetics

Volumn 5, Issue JUN, 2014, Pages

  Sandi, Chiranjeevi ^a,b   Sandi, Madhavi ^a   Virmouni, Sara Anjomani ^a   Al Mahdawi, Sahar ^a   Pook, Mark A ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

DNA demethylation; Frataxin; FRDA; Friedreich ataxia; FXN; GAA repeat; HDAC inhibitor; HMTase inhibitor

Indexed keywords

2 AMINOBENZAMIDE; 2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL) PROPOXY] 4 QUINAZOLINAMINE; 2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY] 4 QUINAZOLINAMINE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BML 210; BUTYRIC ACID; COMPLEMENTARY RNA; DNA METHYLTRANSFERASE; FRATAXIN; GSK126; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; HISTONE METHYLTRANSFERASE; MG 98; MITHRAMYCIN; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1, 4 DIAZEPIN 1 YL) 6, 7 DIMETHOXY 4 QUINAZOLINAMINE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; NICOTINAMIDE; OXAMFLATIN; PANOBINOSTAT; RESVERATROL; RG2833; SIRTINOL; SPLITOMICIN; TRANSCRIPTION FACTOR CTCF; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZEBULARINE;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DEMETHYLATION; DNA HYDROXYMETHYLATION; DNA METHYLATION; EPIGENETICS; FRIEDREICH ATAXIA; FXN GENE; GENE; GENE SILENCING; HISTONE MODIFICATION; HUMAN; MOLECULAR THERAPY; NONHUMAN; PROTEIN PROCESSING; REVIEW; RISK FACTOR; TRANSCRIPTION INITIATION;

EID: 84906273771     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00165     Document Type: Review

References (100)

1. Al-Mahdawi, S., Pinto, R. M., Ismail, O., Varshney, D., Lymperi, S., Sandi, C., et al. (2008). The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet . 17, 735-746. doi: 10.1093/hmg/ddm346
2. Al-Mahdawi, S., Sandi, C., Mouro Pinto, R., and Pook, M. A. (2013). Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus. PLoS ONE 8:e74956. doi: 10.1371/journal.pone.0074956
3. Bandiera, S., Cartault, F., Jannot, A.-S., Hatem, E., Girard, M., Rifai, L., et al. (2013). Genetic variations creating microRNA target sites in the FXN 3'-UTR affect Frataxin expression in Friedreich ataxia. PLoS ONE 8:e54791. doi: 10.1371/journal.pone.0054791
4. Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837. doi: 10.1016/j.cell.2007.05.009
5. Biacsi, R., Kumari, D., and Usdin, K. (2008). SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet . 4:e1000017. doi: 10.1371/journal.pgen.1000017
6. Bradley, J. L., Blake, J. C., Chamberlain, S., Thomas, P. K., Cooper, J. M., and Schapira, A. H. (2000). Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet . 9, 275-282. doi: 10.1093/hmg/9.2.275
7. Butler, R., and Bates, G. P. (2006). Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci . 7, 784-796. doi: 10.1038/nrn1989
8. Campuzano, V., Montermini, L., Lutz, Y., Cova, L., Hindelang, C., Jiralerspong, S., et al. (1997). Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet . 6, 1771-1780. doi: 10.1093/hmg/6.11.1771
9. Campuzano, V., Montermini, L., Molto, M. D., Pianese, L., Cossee, M., Cavalcanti, F., et al. (1996). Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427. doi: 10.1126/science.271.5254.1423
10. Castaldo, I., Pinelli, M., Monticelli, A., Acquaviva, F., Giacchetti, M., Filla, A., et al. (2008). DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J. Med. Genet . 45, 808-812. doi: 10.1136/jmg.2008.058594
11. Chan, P. K., Torres, R., Yandim, C., Law, P. P., Khadayate, S., Mauri, M., et al. (2013). Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum. Mol. Genet . 22, 2662-2675. doi: 10.1093/hmg/ddt115
12. Chang, Y., Zhang, X., Horton, J. R., Upadhyay, A. K., Spannhoff, A., Liu, J., et al. (2009). Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol . 16, 312-317. doi: 10.1038/nsmb.1560
13. Chiurazzi, P., Pomponi, M. G., Pietrobono, R., Bakker, C. E., Neri, G., and Oostra, B. A. (1999). Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum. Mol. Genet . 8, 2317-2323. doi: 10.1093/hmg/8.12.2317
14. Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A., and Neri, G. (1998). In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet . 7, 109-113. doi: 10.1093/hmg/7.1.109
15. Cho, D. H., Thienes, C. P., Mahoney, S. E., Analau, E., Filippova, G. N., and Tapscott, S. J. (2005). Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 20, 483-489. doi: 10.1016/j.molcel.2005.09.002
16. Chou, C. J., Herman, D., and Gottesfeld, J. M. (2008). Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem . 283, 35402-35409. doi: 10.1074/jbc.M807045200
17. Chung, D. W., Rudnicki, D. D., Yu, L., and Margolis, R. L. (2011). A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum. Mol. Genet . 20, 3467-3477. doi: 10.1093/hmg/ddr263
18. Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis . 14, 27-41. doi: 10.1016/j.jalz.2008.05.420
19. De Biase, I., Chutake, Y. K., Rindler, P. M., and Bidichandani, S. I. (2009). Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS ONE 4:e7914. doi: 10.1371/journal.pone.0007914
20. Engel, N., Thorvaldsen, J. L., and Bartolomei, M. S. (2006). CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/Igf2 locus. Hum. Mol. Genet . 15, 2945-2954. doi: 10.1093/hmg/ddl237
21. Evans-Galea, M. V., Carrodus, N., Rowley, S. M., Corben, L. A., Tai, G., Saffery, R., et al. (2012). FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann. Neurol . 71, 487-497. doi: 10.1002/ana.22671
22. Festenstein, R. (2006). Breaking the silence in Friedreich's ataxia. Nat. Chem. Biol . 2, 512-513. doi: 10.1038/nchembio1006-512
23. Filippova, G. N., Cheng, M. K., Moore, J. M., Truong, J. P., Hu, Y. J., Nguyen, D. K., et al. (2005). Boundaries between chromosomal domains of X inactivation and escape bind CTCF and lack CpG methylation during early development. Dev. Cell 8, 31-42. doi: 10.1016/j.devcel.2004.10.018
24. Filippova, G. N., Thienes, C. P., Penn, B. H., Cho, D. H., Hu, Y. J., Moore, J. M., et al. (2001). CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus. Nat. Genet . 28, 335-343. doi: 10.1038/ng570
25. Foury, F., and Cazzalini, O. (1997). Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett . 411, 373-377. doi: 10.1016/S0014-5793(97)00734-5
26. Garbes, L., Riessland, M., Holker, I., Heller, R., Hauke, J., Trankle, C., et al. (2009). LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet . 18, 3645-3658. doi: 10.1093/hmg/ddp313
27. Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492. doi: 10.1126/science.1083558
28. Ghosh, S., and Feany, M. B. (2004). Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum. Mol. Genet . 13, 2011-2018. doi: 10.1093/hmg/ddh214
29. Grabczyk, E., Mancuso, M., and Sammarco, M. C. (2007). A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro . Nucleic Acids Res . 35, 5351-5359. doi: 10.1093/nar/gkm589
30. Greene, E., Mahishi, L., Entezam, A., Kumari, D., and Usdin, K. (2007). Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res . 35, 3383-3390. doi: 10.1093/nar/gkm271
31. Guo, J. U., Su, Y., Zhong, C., Ming, G. L., and Song, H. (2011). Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434. doi: 10.1016/j.cell.2011.03.022
32. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., and Gottesfeld, J. M. (2006). Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol . 2, 551-558. doi: 10.1038/nchembio815
33. Holwerda, S. J., and De Laat, W. (2013). CTCF: the protein, the binding partners, the binding sites and their chromatin loops. Philos. Trans. R. Soc. Lond. B Biol. Sci . 368:20120369. doi: 10.1098/rstb.2012.0369
34. Jain, N., Rossi, A., and Garcia-Manero, G. (2009). Epigenetic therapy of leukemia: an update. Int. J. Biochem. Cell Biol . 41, 72-80. doi: 10.1016/j.biocel.2008
35. Janowski, B. A., Hu, J., and Corey, D. R. (2006). Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. Nat. Protoc . 1, 436-443. doi: 10.1038/nprot.2006.64
36. Janowski, B. A., Younger, S. T., Hardy, D. B., Ram, R., Huffman, K. E., and Corey, D. R. (2007). Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol . 3, 166-173. doi: 10.1038/nchembio860
37. Jenuwein, T. (2006). The epigenetic magic of histone lysine methylation. FEBS J . 273, 3121-3135. doi: 10.1111/j.1742-4658
38. Khalil, A. M., Faghihi, M. A., Modarresi, F., Brothers, S. P., and Wahlestedt, C. (2008). A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS ONE 3:e1486. doi: 10.1371/journal.pone.0001486
39. Kim, E., Napierala, M., and Dent, S. Y. (2011). Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia. Nucleic Acids Res . 39, 8366-8377. doi: 10.1093/nar/gkr542
40. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M., and Horinouchi, S. (1999). Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461-2470. doi: 10.1038/sj.onc.1202564
41. Kimura, A., Matsubara, K., and Horikoshi, M. (2005). A decade of histone acetylation: marking eukaryotic chromosomes with specific codes. J. Biochem . 138, 647-662. doi: 10.1093/jb/mvi184
42. Koeppen, A. H., Michael, S. C., Knutson, M. D., Haile, D. J., Qian, J., Levi, S., et al. (2007). The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol . 114, 163-173. doi: 10.1007/s00401-007-0220-y
43. Kourmouli, N., Jeppesen, P., Mahadevhaiah, S., Burgoyne, P., Wu, R., Gilbert, D. M., et al. (2004). Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J. Cell Sci . 117, 2491-2501. doi: 10.1242/jcs.01238
44. Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705. doi: 10.1016/j.cell.2007.02.005
45. Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929-930. doi: 10.1126/science.1169786
46. Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., et al. (2007). Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481. doi: 10.1016/j.molcel.2007.01.017
47. Kumari, D., Biacsi, R. E., and Usdin, K. (2011). Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells. J. Biol. Chem . 286, 4209-4215. doi: 10.1074/jbc.M110.194035
48. Ladd, P. D., Smith, L. E., Rabaia, N. A., Moore, J. M., Georges, S. A., Hansen, R. S., et al. (2007). An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum. Mol. Genet . 16, 3174-3187. doi: 10.1093/hmg/ddm293
49. Lee, S. T., Chu, K., Im, W. S., Yoon, H. J., Im, J. Y., Park, J. E., et al. (2011). Altered microRNA regulation in Huntington's disease models. Exp. Neurol . 227, 172-179. doi: 10.1016/j.expneurol.2010.10.012
50. Li, H., Rauch, T., Chen, Z. X., Szabo, P. E., Riggs, A. D., and Pfeifer, G. P. (2006). The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biol. Chem . 281, 19489-19500. doi: 10.1074/jbc.M513249200
51. Li, K., Singh, A., Crooks, D. R., Dai, X., Cong, Z., Pan, L., et al. (2010). Expression of human Frataxin is regulated by transcription factors SRF and TFAP2. PLoS ONE 5:e12286. doi: 10.1371/journal.pone.0012286
52. Li, L., Voullaire, L., Sandi, C., Pook, M. A., Ioannou, P. A., Delatycki, M. B., et al. (2013). Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS ONE 8:e55940. doi: 10.1371/journal.pone.0055940
53. Libby, R. T., Hagerman, K. A., Pineda, V. V., Lau, R., Cho, D. H., Baccam, S. L., et al. (2008). CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet . 4:e1000257. doi: 10.1371/journal.pgen.1000257
54. Lorincz, M. C., Dickerson, D. R., Schmitt, M., and Groudine, M. (2004). Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat. Struct. Mol. Biol . 11, 1068-1075. doi: 10.1038/nsmb840
55. Lufino, M. M., Silva, A. M., Nemeth, A. H., Alegre-Abarrategui, J., Russell, A. J., and Wade-Martins, R. (2013). A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds. Hum. Mol. Genet . 22, 5173-5187. doi: 10.1093/hmg/ddt370
56. Machleidt, T., Robers, M. B., Hermanson, S. B., Dudek, J. M., and Bi, K. (2011). TR-FRET cellular assays for interrogating posttranslational modifications of histone H3. J. Biomol. Screen . 16, 1236-1246. doi: 10.1177/1087057111422943
57. Mahishi, L. H., Hart, R. P., Lynch, D. R., and Ratan, R. R. (2012). miR-886-3p levels are elevated in Friedreich ataxia. J. Neurosci . 32, 9369-9373. doi: 10.1523/JNEUROSCI.0059-12.2012
58. Martelli, A., Napierala, M., and Puccio, H. (2012). Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models. Dis. Model. Mech . 5, 165-176. doi: 10.1242/dmm.008706
59. Martin, C., and Zhang, Y. (2005). The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol . 6, 838-849. doi: 10.1038/nrm1761
60. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112. doi: 10.1038/nature11606
61. McGarvey, K. M., Fahrner, J. A., Greene, E., Martens, J., Jenuwein, T., and Baylin, S. B. (2006). Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res . 66, 3541-3549. doi: 10.1158/0008-5472.CAN-05-2481
62. Moseley, M. L., Zu, T., Ikeda, Y., Gao, W., Mosemiller, A. K., Daughters, R. S., et al. (2006). Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet . 38, 758-769. doi: 10.1038/ng1827
63. Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247-257. doi: 10.1016/S0092-8674(00)81656-6
64. Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., et al. (2006). Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176-185. doi: 10.1038/sj.onc.1209049
65. Pandolfo, M. (2008). Friedreich ataxia. Arch. Neurol . 65, 1296-1303. doi: 10.1001/archneur.65.10.1296
66. Pianese, L., Turano, M., Lo Casale, M. S., De Biase, I., Giacchetti, M., Monticelli, A., et al. (2004). Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J. Neurol. Neurosurg. Psychiatr . 75, 1061-1063. doi: 10.1136/jnnp.2003.028605
67. Plummer, R., Vidal, L., Griffin, M., Lesley, M., De Bono, J., Coulthard, S., et al. (2009). Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res . 15, 3177-3183. doi: 10.1158/1078-0432.CCR-08-2859
68. Pradhan, S., Bacolla, A., Wells, R. D., and Roberts, R. J. (1999). Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J. Biol. Chem . 274, 33002-33010. doi: 10.1074/jbc.274.46.33002
69. Punga, T., and Buhler, M. (2010). Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol. Med . 2, 120-129. doi: 10.1002/emmm.201000064
70. Rai, M., Soragni, E., Chou, C. J., Barnes, G., Jones, S., Rusche, J. R., et al. (2010). Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS ONE 5:e8825. doi: 10.1371/journal.pone.0008825
71. Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Coppola, G., et al. (2008). HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3:e1958. doi: 10.1371/journal.pone.0001958
72. Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-599. doi: 10.1038/35020506
73. Robertson, K. D. (2001). DNA methylation, methyltransferases, and cancer. Oncogene 20, 3139-3155. doi: 10.1038/sj.onc.1204341
74. Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., et al. (2006). ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A . 103, 19176-19181. doi: 10.1073/pnas.0606373103
75. Sandi, C., Al-Mahdawi, S., and Pook, M. A. (2013). Epigenetics in Friedreich's ataxia: challenges and opportunities for therapy. Genet. Res. Int . 2013, 12. doi: 10.1155/2013/852080
76. Sandi, C., Pinto, R. M., Al-Mahdawi, S., Ezzatizadeh, V., Barnes, G., Jones, S., et al. (2011). Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis . 42, 496-505. doi: 10.1016/j.nbd.2011.02.016
77. Sandi, C., Sandi, M., Jassal, H., Ezzatizadeh, V., Anjomani-Virmouni, S., Al-Mahdawi, S., et al. (2014). Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models. PLoS ONE 9:e89488. doi: 10.1371/journal.pone.0089488
78. Sarsero, J. P., Li, L., Wardan, H., Sitte, K., Williamson, R., and Ioannou, P. A. (2003). Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med . 5, 72-81. doi: 10.1002/jgm.320
79. Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., et al. (2013). PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci. Rep . 3, 1911. doi: 10.1038/srep01911
80. Saveliev, A., Everett, C., Sharpe, T., Webster, Z., and Festenstein, R. (2003). DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422, 909-913. doi: 10.1038/nature01596
81. Schulz, J. B., Boesch, S., Burk, K., Durr, A., Giunti, P., Mariotti, C., et al. (2009). Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol . 5, 222-234. doi: 10.1038/nrneurol.2009.26
82. Sharma, R., De Biase, I., Gomez, M., Delatycki, M. B., Ashizawa, T., and Bidichandani, S. I. (2004). Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann. Neurol . 56, 898-901. doi: 10.1002/ana.20333
83. Shen, Y., Yue, F., McCleary, D. F., Ye, Z., Edsall, L., Kuan, S., et al. (2012). A map of the cis-regulatory sequences in the mouse genome. Nature 488, 116-120. doi: 10.1038/nature11243
84. Sopher, B. L., Ladd, P. D., Pineda, V. V., Libby, R. T., Sunkin, S. M., Hurley, J. B., et al. (2011). CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 70, 1071-1084. doi: 10.1016/j.neuron.2011.05.027
85. Soragni, E., Herman, D., Dent, S. Y., Gottesfeld, J. M., Wells, R. D., and Napierala, M. (2008). Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res . 36, 6056-6065. doi: 10.1093/nar/gkn604
86. Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., and Gottesfeld, J. M. (2012). Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J. Child Neurol . 27, 1164-1173. doi: 10.1177/0883073812448533
87. Stack, E. C., Del Signore, S. J., Luthi-Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S., et al. (2007). Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet . 16, 1164-1175. doi: 10.1093/hmg/ddm064
88. Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., and Piekarz, R. L. (2010). Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3, 2751-2767. doi: 10.3390/ph3092751
89. Szulwach, K. E., Li, X., Li, Y., Song, C. X., Wu, H., Dai, Q., et al. (2011). 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci . 14, 1607-1616. doi: 10.1038/nn.2959
90. Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935. doi: 10.1126/science.1170116
91. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., et al. (2008). The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A . 105, 15564-15569. doi: 10.1073/pnas.0804249105
92. Vedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, A., Labrie, V., et al. (2011). A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol . 7, 566-574. doi: 10.1038/nchembio.599
93. Wagner, G. R., Pride, P. M., Babbey, C. M., and Payne, R. M. (2012). Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase. Hum. Mol. Genet . 21, 2688-2697. doi: 10.1093/hmg/dds095
94. Waldvogel, D., Van Gelderen, P., and Hallett, M. (1999). Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol . 46, 123-125.
95. Wang, H., Maurano, M. T., Qu, H., Varley, K. E., Gertz, J., Pauli, F., et al. (2012). Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res . 22, 1680-1688. doi: 10.1101/gr.136101.111
96. Watts, J. K., Yu, D., Charisse, K., Montaillier, C., Potier, P., Manoharan, M., et al. (2010). Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res . 38, 5242-5259. doi: 10.1093/nar/gkq258
97. Wells, R. D. (2008). DNA triplexes and Friedreich ataxia. FASEB J . 22, 1625-1634. doi: 10.1096/fj.07-097857
98. Wong, A., Yang, J., Cavadini, P., Gellera, C., Lonnerdal, B., Taroni, F., et al. (1999). The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet . 8, 425-430. doi: 10.1093/hmg/8.3.425
99. Xia, H., Cao, Y., Dai, X., Marelja, Z., Zhou, D., Mo, R., et al. (2012). Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia. PLoS ONE 7:e47847. doi: 10.1371/journal.pone.0047847
100. Xu, C., Soragni, E., Chou, C. J., Herman, D., Plasterer, H. L., Rusche, J. R., et al. (2009). Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem. Biol . 16, 980-989. doi: 10.1016/j.chembiol.2009.07.010